Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.

Jayesh Desai; Tarek Meniawy; Brandon Beagle; ZheZhen Li; Song Mu; John Wu; Crystal S. Denlinger; Wells A. Messersmith

Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.

Jayesh Desai, Tarek Meniawy, Brandon Beagle, ZheZhen Li, Song Mu, John Wu, Crystal S. Denlinger, Wells A. Messersmith

Internal Medicine

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

8 Citations (Web of Science)

Original language	English
Number of pages	2
Journal	Journal of Clinical Oncology
Volume	38
Issue number	15
Publication status	Published - 20 May 2020
Event	56th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Duration: 29 May 2020 → 31 May 2020

Cite this

@article{526b9e4495aa4f06ac6fcc60b6cd41f1,

title = "Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.",

author = "Jayesh Desai and Tarek Meniawy and Brandon Beagle and ZheZhen Li and Song Mu and John Wu and Denlinger, {Crystal S.} and Messersmith, {Wells A.}",

year = "2020",

month = may,

day = "20",

language = "English",

volume = "38",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15",

note = "56th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) ; Conference date: 29-05-2020 Through 31-05-2020",

}

Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress. / Desai, Jayesh; Meniawy, Tarek; Beagle, Brandon et al.
In: Journal of Clinical Oncology, Vol. 38, No. 15, 20.05.2020.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors

T2 - 56th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

AU - Desai, Jayesh

AU - Meniawy, Tarek

AU - Beagle, Brandon

AU - Li, ZheZhen

AU - Mu, Song

AU - Wu, John

AU - Denlinger, Crystal S.

AU - Messersmith, Wells A.

PY - 2020/5/20

Y1 - 2020/5/20

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.TPS3146

M3 - Abstract/Meeting Abstract

SN - 0732-183X

VL - 38

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

Y2 - 29 May 2020 through 31 May 2020

ER -

Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.

Other files and links

Cite this